Your browser is no longer supported. Please, upgrade your browser.
GSK GlaxoSmithKline plc daily Stock Chart
GlaxoSmithKline plc
Index- P/E39.21 EPS (ttm)1.05 Insider Own0.20% Shs Outstand2.44B Perf Week0.37%
Market Cap100.00B Forward P/E14.30 EPS next Y2.87 Insider Trans0.00% Shs Float2.44B Perf Month2.73%
Income2.56B PEG3.41 EPS next Q0.83 Inst Own9.70% Short Float0.28% Perf Quarter-4.12%
Sales39.56B P/S2.53 EPS this Y-89.20% Inst Trans-0.02% Short Ratio2.17 Perf Half Y0.74%
Book/sh0.44 P/B93.20 EPS next Y-0.07% ROA3.30% Target Price46.33 Perf Year-1.80%
Cash/sh2.21 P/C18.53 EPS next 5Y11.50% ROE204.00% 52W Range37.20 - 44.53 Perf YTD6.49%
Dividend1.99 P/FCF32.80 EPS past 5Y-28.90% ROI8.60% 52W High-7.92% Beta1.01
Dividend %4.85% Quick Ratio0.40 Sales past 5Y0.40% Gross Margin69.00% 52W Low10.24% ATR0.30
Employees99827 Current Ratio0.60 Sales Q/Q12.10% Oper. Margin12.60% RSI (14)66.16 Volatility0.67% 0.67%
OptionableYes Debt/Eq23.27 EPS Q/Q58.80% Profit Margin6.50% Rel Volume1.07 Prev Close40.83
ShortableYes LT Debt/Eq15.12 EarningsOct 25 Payout153.90% Avg Volume3.18M Price41.01
Recom2.00 SMA200.84% SMA502.41% SMA200-0.58% Volume3,415,952 Change0.44%
Sep-08-17Downgrade Morgan Stanley Equal-Weight → Underweight
Jul-05-17Downgrade Citigroup Buy → Neutral
May-26-17Upgrade Berenberg Hold → Buy
Apr-05-17Upgrade Exane BNP Paribas Underperform → Neutral
Mar-09-17Initiated Liberum Buy
Mar-09-17Initiated Kepler Reduce
Oct-20-16Initiated Investec Buy
Sep-23-16Initiated Piper Jaffray Overweight
Jul-14-16Upgrade Jefferies Hold → Buy
Mar-30-16Upgrade Citigroup Neutral → Buy
Feb-26-16Initiated Cantor Fitzgerald Hold
Dec-09-15Upgrade BofA/Merrill Neutral → Buy
Dec-07-15Reiterated Argus Buy $52 → $48
Oct-20-15Upgrade Credit Suisse Underperform → Neutral
Sep-15-15Upgrade Exane BNP Paribas Underperform → Neutral
Sep-08-15Upgrade BofA/Merrill Underperform → Neutral
Jun-26-15Upgrade Liberum Sell → Hold
Jun-04-15Downgrade Morgan Stanley Overweight → Equal-Weight
May-20-15Resumed Citigroup Neutral
Apr-15-15Initiated Societe Generale Sell
Oct-18-17 04:21PM  What to Expect from Big Pharmas After J&J's Solid Q3 Results? Zacks
07:42AM  What GlaxoSmithKlines 3Q17 Performance Tells Us Market Realist
Oct-16-17 06:07PM  Glaxo's Shingles Vaccine Shingrix Gets Approval in Canada Zacks
Oct-13-17 04:14PM  5 Large-Cap Drug Stocks Well Poised to Beat on Q3 Earnings Zacks
03:00PM  GlaxoSmithKline's shingles vaccine gets approval in Canada Reuters
Oct-12-17 06:32PM  Pharma companies are starting to recruit top talent from tech giants like Google and LinkedIn CNBC
Oct-11-17 05:31PM  [$$] Ebola Vaccines Show Promise in New Study The Wall Street Journal
Oct-08-17 07:27PM  May to consult business leaders on Brexit Reuters
09:00AM  3 High-Yield Healthcare Stocks Motley Fool
Oct-06-17 01:36AM  [$$] Consumer drugs do not always work for big pharma Financial Times
Oct-05-17 10:38AM  Changes in GlaxoSmithKlines Valuation Market Realist
09:08AM  Performance of GlaxoSmithKlines Consumer Healthcare Segment Market Realist
07:39AM  Quarterly Performance of GlaxoSmithKlines Vaccines Segment Market Realist
Oct-04-17 12:11PM  Emergent Completes Acquisition of Anthrax Drug Raxibacumab Zacks
10:39AM  Quarterly Performance of GlaxoSmithKlines Global Pharmaceuticals Market Realist
09:10AM  Quarterly Performance for GlaxoSmithKlines HIV Business Market Realist
07:43AM  GlaxoSmithKlines Pharmaceuticals Segment in 2Q17 Market Realist
Oct-03-17 04:36PM  Quarterly Performance of GlaxoSmithKlines Segments Market Realist
03:06PM  GlaxoSmithKlines Quarterly Revenues Market Realist
01:17PM  GlaxoSmithKlines Recent 3Q17 Developments Market Realist
07:00AM  Emergent BioSolutions Completes Acquisition of Raxibacumab, an FDA-Approved Anthrax Monoclonal Antibody, From GSK GlobeNewswire
Oct-02-17 04:27PM  U.S. judge dismisses ex-sleuths' lawsuit against GlaxoSmithKline Reuters
Sep-28-17 10:51AM  Attention Biotech Investors, Here's Your PDUFA Primer For October Benzinga
09:20AM  Agenus (AGEN) Remains Focused on Drug Development Programs Zacks
Sep-27-17 09:05AM  AstraZeneca's Bevespi Improves Lung Function in Phase III Study Zacks
07:37AM  What Happened to Allergans Valuation after 2Q17? Market Realist
Sep-26-17 03:00PM  Biotech's Boy Wonder Calls Alzheimer's Drug His 'Single Greatest Failure' Forbes
09:00AM  3 High-Yield Stocks for Conservative Investors Motley Fool
07:14AM  Axovant Alzheimer's Drug Fails To Help Patients Forbes
Sep-25-17 10:25AM  UPDATE 2-FDA declines to approve J&J arthritis drug sirukumab Reuters
Sep-22-17 08:42AM  Pharma Stock Roundup: Pfizer Files Suit against J&J, Supernus Hit by Study Update Zacks
Sep-21-17 09:44AM  Glaxo-Innoviva's Triple Combo Inhaler Positive in Phase III Zacks
08:33AM  How GlaxoSmithKline (GSK) Stock Stands Out in a Strong Industry Zacks
Sep-20-17 09:40AM  Is GlaxoSmithKline plc (GSK) a Suitable Value Stock? Zacks
03:17AM  GSK's new triple lung drug beats other modern inhalers in study Reuters
02:00AM  GSK and Innoviva Report Positive Headline Results from IMPACT Study Showing Single Inhaler Triple Therapy Trelegy Ellipta Reduced COPD Exacerbations Business Wire
Sep-19-17 04:40PM  FDA OKs Glaxo's inhaler, first one to combine 3 medicines Associated Press
03:05PM  Glaxo/Innoviva's Triple Combo Therapy Gets FDA Nod for COPD Zacks
01:26PM  [$$] Andrew Witty jumps into biotech venture capital Financial Times
04:02AM  GlaxoSmithKline breathes easier as U.S. approves triple lung drug Reuters
Sep-18-17 08:30PM  Trelegy Ellipta approved as the first once-daily single inhaler triple therapy for the treatment of appropriate patients with COPD in the US PR Newswire
07:18PM  U.S. FDA approves GSK's three-in-one drug inhaler for COPD Reuters
06:29PM  Trelegy Ellipta Approved as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Appropriate Patients with COPD in the US Business Wire
02:19PM  What Analysts Recommend for Novartis in September 2017 Market Realist
10:30AM  3 High-Yield Healthcare Stocks Motley Fool
10:23AM  Glaxo's Triple Therapy COPD Inhaler Gets CHMP Nod in the EU Zacks
Sep-15-17 10:24AM  France's Neovacs takes on GSK and AstraZeneca in battle to treat lupus Reuters
06:52AM  Pharma Stock Roundup: Achillion Slumps on End of HCV Deal, Teva Gets a New CEO Zacks
03:23AM  GSK's three-in-one inhaler gets positive opinion from EU agency Reuters
02:44AM  GSK's three-in-one inhaler gets positive opinion from EU agency Reuters
02:00AM  Trelegy Ellipta Once-Daily Single Inhaler Triple Therapy Receives Positive Opinion from the CHMP in Europe for Appropriate Patients with COPD Business Wire
Sep-14-17 11:25AM  Glaxo's Shingles Candidate Gets Positive FDA Committee Vote Zacks
07:40AM  Corporate News Blog - GlaxoSmithKline Declares Publication of Phase-III Results Of Mepolizumab in Patients with Eosinophilic COPD at Risk of Exacerbations ACCESSWIRE
Sep-13-17 03:49PM  'Impressed' FDA panel unanimously recommends GSK shingles vaccine Reuters
03:49PM  FDA Advisory Committee votes unanimously for Shingrix (HZ/su) in the US for prevention of herpes zoster (shingles) in adults ages 50 and over PR Newswire
02:23PM  FDA panel unanimously votes to recommend GSK shingles vaccine Reuters
Sep-12-17 05:23PM  GlaxoSmithKline Plc : GSK-US: Dividend Analysis : August 11th, 2017 (record date) : By the numbers : September 12, 2017 Capital Cube
03:55AM  When Should You Buy GlaxoSmithKline plc (LSE:GSK)? Simply Wall St.
Sep-11-17 10:36AM  How Mercks Gardasil and Other Human Vaccines Performed in 2Q17 Market Realist
03:01AM  Positive Results from Pioneering Salford Lung Study in Asthma Published in The Lancet, and Presented at European Respiratory Congress Business Wire
Sep-08-17 07:18AM  Better Buy: AbbVie Inc. vs. GlaxoSmithKline plc Motley Fool
Sep-07-17 07:30AM  GSK Exercises Option over SPEAR T-cell Therapy Program Targeting NY-ESO GlobeNewswire
06:04AM  5 Things Gilead Sciences' Management Just Said That You'll Want to Know Motley Fool
Sep-06-17 12:19AM  Germanys Merck Puts Consumer Drugs Business on the Block The Wall Street Journal
Sep-05-17 04:37PM  Narasimhan to Replace Jimenez as Novartis (NVS) CEO in 2018 Zacks
10:36AM  Performance of AstraZenecas Respiratory Segment in 2Q17 Market Realist
Sep-04-17 08:05AM  Key FDA Regulatory Events to Watch Out for in Sep 2017 Zacks
07:36AM  GlaxoSmithKlines Consumer Healthcare Business Improved Market Realist
Sep-01-17 10:37AM  GlaxoSmithKlines Vaccines Business in 2Q17 Market Realist
09:07AM  Analyzing GlaxoSmithKlines Global Pharmaceuticals Business Market Realist
09:06AM  Promacta: A Major Growth Driver for Ligand Pharmaceuticals in 2017 Market Realist
07:38AM  GlaxoSmithKlines HIV Business in 2Q17 Market Realist
06:02AM  GlaxoSmithKline Is Wasting Money Paying a Dividend Motley Fool
Aug-31-17 07:01PM  GlaxoSmithKline's 5% Yield Carries Considerable Risk
03:35PM  Why GlaxoSmithKlines Pharmaceuticals Business Grew Market Realist
02:06PM  How Did GlaxoSmithKlines Segments Perform in 2Q17? Market Realist
12:34PM  GlaxoSmithKline Reported Revenue Growth in 2Q17 Market Realist
12:34PM  Changes in GlaxoSmithKlines Valuation after 2Q17 Market Realist
Aug-30-17 02:54PM  Behind Novartiss Valuation after 2Q17 Market Realist
09:55AM  GlaxoSmithKline Recent Pullback Delivers A Healthy Opportunity To Buy Benzinga
Aug-28-17 06:01AM  A Serious Reaction After Vaccination Rarely Occurs Again With Later Immunization, Study Finds Forbes
Aug-24-17 02:56AM  Novartis picks retail expert for new role of digital chief Reuters
Aug-23-17 09:47AM  Are Glaxo's Successful New Drugs Enough to Drive Growth? Zacks
08:31AM  The Zacks Analyst Blog Highlights: Allergan, Ecolab, Exelon, GlaxoSmithKline and Rockwell Collins Zacks
Aug-22-17 06:05PM  Perrigo's (PRGO) OTC Version of Nexium Secures FDA Approval Zacks
05:15PM  Top Analyst Reports for Allergan, Ecolab & Exelon Zacks
06:30AM  3 High-Yield Pharmaceutical Stocks Motley Fool
Aug-21-17 04:00PM  3 High-Yield Stocks to Own in a Market Crash Motley Fool
05:36AM  [$$] The questionable strategy of a pharmaceuticals CEO Financial Times
Aug-18-17 04:18PM  Mylan Finalizes Settlement Agreement with DOJ for $465M Zacks
Aug-15-17 04:55AM  Shire Gains as it Seeks European Approval For Dry Eye Treatment
Aug-14-17 01:39PM  [$$] The key to innovation is balancing risk and rigour Financial Times
10:14AM  What Happened In Biotech Last Week?
08:32AM  Ionis Pharmaceuticals Retains Rights to Inotersen, Stock Up Zacks
Aug-13-17 12:49PM  Stocks That Fell to 3-Year Lows in the Week of August 11
Aug-12-17 02:51PM  Where Does Zika Virus Vaccine Research Stand Now? Benzinga
Aug-11-17 05:36PM  ETFs with exposure to GlaxoSmithKline Plc : August 11, 2017 Capital Cube
04:07PM  Ionis Pharmaceuticals Inc: Growing Royalties, an Advancing Pipeline, and Getting Back Rights to Some Drugs Motley Fool
10:01AM  Biotech movers: Ionis Drops After GSK Bows Out of Partnership
Aug-10-17 01:39PM  Former GSK exec resigns from Intellia board due to 'conflict' American City Business Journals
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories under the Otrivin, Panadol, parodontax, Poligrip, Sensodyne, Theraflu, and Voltaren brand names. The company offers its consumer healthcare products in the form of tablets, caplets, infant syrup drops, topical gels, nasal sprays, effervescents, lozenges, gum and trans-dermal patches, malted drinks and foods, and topical creams and non-medicated patches, as well as toothpastes, toothbrushes, mouth rinses, medicated mouthwashes, gels and sprays, denture adhesives, and denture cleansers. GlaxoSmithKline plc has a strategic drug discovery collaboration with Exscientia Limited to discover novel and selective small molecules for up to 10 disease-related targets across various therapeutic areas; and a collaboration agreement with Oklahoma Medical Research Foundation for the discovery, development, and commercialization of therapies to prevent organ damage and death caused by acute pancreatitis, lung injury, and trauma conditions. The company was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GLAXOSMITHKLINE PLC10% OwnerOct 24Buy14.0066,500931,0003,220,627Oct 26 05:49 PM